TMCnet

Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

“Completing Phase 1 and the decision by Neurosterix to progress NTX-253 into Phase 2 studies in schizophrenia patients is a significant achievement,” said Tim Dyer, CEO of Addex. “The well-designed ...

Addex (ADXN) Q2 2026 Earnings Call Transcript

Welcome to the Addex Therapeutics Report 2026 Half-Year Financial Results and Provides Corporate Update Webcast and Conference Call. At this time, all participants are in a listen-only mode. After the ...
Pulse 2.0

Addex Therapeutics Raises $2.8 Million As GABAB Programs Advance

Addex Therapeutics reported its first-half 2026 results while outlining progress across its neurological drug portfolio, including $2.8 million raised through an at-the-market offering and the return ...
Fierce Biotech

Indivior ends PAM drug collab with Addex ahead of Supernus merger

Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs). Their ...
Financial Times

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

Geneva, Switzerland, July 8, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...

Addex Raises Fresh Funds as It Regains GABAB Rights and Advances CNS Pipeline

Addex Therapeutics ( ) has provided an update. Addex Therapeutics reported its 2026 half-year results, highlighting a tighter financial position alongside strategic progress in it ...
Business Insider

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

Geneva, Switzerland, August 26, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
RTTNews

Addex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia Trial

Addex Therapeutics ( ADXN) announced that its spin-out company Neurosterix has completed Phase 1 clinical studies of NTX-253, an investigational positive allosteric modulator (PAM) of the muscarinic ...
Yahoo Finance

Addex Therapeutics Announces Executive Management Changes

Geneva, Switzerland, October 2, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company ...
markets.financialcontent

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric ...
Nasdaq

Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders

Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today ...
Business Insider

Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities

Geneva, Switzerland, January 11, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and ...